Illumina Comments on Roche’s Unsolicited Tender Offer Extension
News Feb 27, 2012
Illumina, Inc. has issued the following statement regarding Roche’s decision to extend its unsolicited tender offer to acquire all outstanding shares of Illumina for $44.50 in cash per common share:
“The extension by Roche was expected. An extremely low number of shares have been tendered, consistent with our view - and that of our stockholders - that Roche’s offer does not reflect Illumina’s unique leadership position, business performance and future prospects.
“We remain focused on continuing to develop breakthrough products that expand existing markets and create new ones. The potential of our industry is enormous, with major new markets emerging in medical diagnostics, reproductive health and cancer management.”
Researchers warn that--as the predictive power of genes tied to learning and educational outcomes increases and access to genetic data expands--researchers, educators, and policymakers must be cautious in how they use such data, interpret related findings, and, in the not-too-distant future, apply genetics-informed student interventions.READ MORE
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE
Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden. According to a new study, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.READ MORE